Thomas Chester
Optometrist · Cleveland, OHNPI 1598778052
Payments from drug & device makers
Across 486 payments — averaging $1617.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$558K
- Ocular Therapeutix, Inc.$168K
- Shire North American Group Inc$19K
- Ivantis, Inc$9K
- Oyster Point Pharma, Inc.$7K
- Tarsus Pharmaceuticals, Inc.$5K
- plus $19K from 19 others
Across 1 payment — averaging $9.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$9
What the payments were for
- Consulting fees$128,55243%
- Speaking & faculty fees$147,74649%
- Travel & lodging$13,9885%
- Food & beverage$9,2923%
- Education$180%
- Entertainment$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 203 | $557,860 |
| Ocular Therapeutix, Inc. | 6 | $168,438 |
| Shire North American Group Inc | 27 | $19,130 |
| Ivantis, Inc | 6 | $9,419 |
| Oyster Point Pharma, Inc. | 29 | $6,701 |
| Tarsus Pharmaceuticals, Inc. | 21 | $5,248 |
| Bausch & Lomb Americas Inc. | 33 | $4,285 |
| AbbVie(2 entities) | 36 | $2,605 |
| Sun Pharmaceutical Industries Inc. | 20 | $2,557 |
| Novartis | 36 | $2,350 |
| Dompe US, Inc. | 11 | $2,346 |
| Nordic Pharma, Inc. | 1 | $2,100 |
| Kala Pharmaceuticals, Inc. | 6 | $774 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $615 |
| Alcon | 23 | $576 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $434 |
| Harrow Eye, LLC | 6 | $173 |
| Mallinckrodt Hospital Products Inc. | 7 | $137 |
| Optos, Inc. | 2 | $64 |
| Eyevance Pharmaceuticals LLC | 4 | $54 |
| Coopervision Inc. | 1 | $52 |
| Carl Zeiss Meditec, Inc. | 1 | $52 |
| Thea Pharma Inc. | 2 | $31 |
| Quidel Corporation | 1 | $24 |
| Rxsight Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEARCARE SYSTEM$148,171
- TearCare SmartLid$69,253
- TEARCARE(TM) (2.2) SYSTEM KIT$69,253
- TearCare$25,702
- XIIDRA$16,200
- TYRVAYA$6,132
- Hydrus Microstent$5,750
- Hydrus$3,600
- MIEBO$2,250
- CEQUA$2,225
- OMNI(R) SURGICAL SYSTEM (US)$2,217
- Oxervate$2,100
- Lacrifill$2,100
- XDEMVY$1,165
- LUMIGAN$1,007
- COMBIGAN$1,007
- RESTASIS$932
- ALPHAGAN P$875
- EYSUVIS$700
- One Series Ultra IOL Delivery System$600
How this compares
$786,040 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $509,509 |
| XdemvyLotilaner | 75 | $145,057 |
| XiidraLifitegrast | 87 | $133,116 |
| RestasisCyclosporine | 41 | $42,300 |
| MieboPerfluorohexyloctane/Pf | 55 | $42,085 |
| TyrvayaVarenicline Tartrate | 27 | $20,629 |
| LumiganBimatoprost | 33 | $17,526 |
| Alphagan PBrimonidine Tartrate | 19 | $7,448 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $5,491 |
| Brimonidine Tartrate | 38 | $3,869 |
| Latanoprost | 141 | $1,822 |
| Prednisolone Acetate | 21 | $782 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $573 |
| Timolol Maleate | 14 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $2,346 | $509,50912 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $4,285 | $175,201142 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $5,248 | $145,05775 claims |
| AbbVieRestasis, Lumigan, Alphagan P | $2,605 | $67,27493 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $6,701 | $20,62927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Cleveland
- Loretta Szczotka-FlynnCleveland$388K
- Sara HitchmanCleveland$20K
- Thomas StokkermansCleveland$12K
- Joseph KeaneyCleveland$11K
- Katherine BickleGranville$3M
- Jennifer FogtColumbus$1.9M
- Jason MillerPowell$1.4M
- Mile BrujicBowling Green$1.3M
- William LayWesterville$891K
- Gregory DenaeyerColumbus$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.